Results 21 to 30 of about 5,788 (178)

Effects of 12-week treatment with Sovodak in patients infected by genotype 1 hepatitis C virus [PDF]

Journal of Research in Clinical Medicine, 2019
Introduction: It has been shown that the combination therapy of Sofosbuvir-Daclatasvir (Sof/Dac) has a high rate of success in the treatment of patients. For the first time, a single pill of Sof/Dac has been formulated in Iran (Sovodak).
Hosein Mehdipour, Yaghoub Moaddab, Khalil Azizian, Morteza Ghojazadeh, Mohammad Hossein Somi   +4 more
doaj   +1 more source

SARS-CoV-2 Papain-like Protease Responsive ZnO/Daclatasvir-Loaded Chitosan/Gelatin Nanofibers as Smart Antimicrobial Medical Textiles: In Silico, In Vitro and Cell Studies

Pharmaceutics, 2023
A significant number of deaths are reported annually worldwide due to microbial and viral infections. The development of protective medical textiles for patients and healthcare professionals has attracted many researchers’ attention.
Mohamed Hamdi, Akram M. Elkashlan, Mohamed A. Hammad, Isra H. Ali   +3 more
doaj   +1 more source

Efficacy and Adverse Effects of Sofosbuvir plus Daclatasvir Therapy in Chronic HCV Patients in Sharkia Governorate, Egypt [PDF]

Afro-Egyptian Journal of Infectious and Endemic Diseases, 2018
Background and study aim: Hepatitis C is the most pressing public health challenge in Egypt with variable prevalence rates among different age groups. This study aimed to detect the efficacy and adverse effects of sofosbuvir plus daclatasvir therapy in ...
Abeer abdelkader, Noha Shahin, Nahla El-Gammal   +2 more
doaj   +1 more source

Efficacy and safety of narlaprevir/ritonavir and daclatasvir non interferon combination in population of Russian patients with chronic hepatitis C [PDF]

Терапевтический архив, 2019
Aim. Evaluate efficacy and safety of a combination of direct - acting antivirals narlaprevir/ritonavir with daclatasvir in patients with viral hepatitis C. Materials and methods.
E A Klimova, E Z Burnevich, V P Chulanov, D A Gusev, O O Znoyko, S N Batskikh, S N Kizlo, N A Mamonova, E P Tarkhova, E N Krasavina, M Yu Samsonov, N D Yushchuk   +11 more
doaj   +1 more source

Novel 6-Aminoquinazolinone Derivatives as Potential Cross GT1-4 HCV NS5B Inhibitors

Viruses, 2022
Chronic hepatitis C virus (HCV) infections are a worldwide medical problem responsible for diverse types of liver diseases. The NS5B polymerase enzyme has become a very interesting target for the development of anti-HCV drugs owing to its fundamental ...
Tamer Nasr, Ahmed M. Aboshanab, George Mpekoulis, Antonios Drakopoulos, Niki Vassilaki, Grigoris Zoidis, Khaled A. M. Abouzid, Wafaa Zaghary   +7 more
doaj   +1 more source

Daclatasvir and asunaprevir combination therapy for patients with chronic hepatitis C virus genotype 1b infection in real world [PDF]

The Korean Journal of Internal Medicine, 2019
Background/Aims Previous studies have reported a high rate of sustained virologic response (SVR) and a low rate of serious adverse events with the use of daclatasvir (DCV) and asunaprevir (ASV) combination therapy. We evaluated the efficacy and safety of
Jae Young Oh, Byung Seok Kim, Chang Hyeong Lee, Jeong Eun Song, Heon Ju Lee, Jung Gil Park, Jae Seok Hwang, Woo Jin Chung, Byoung Kuk Jang, Young Oh Kweon, Won Young Tak, Soo Young Park, Se Young Jang, Jeong Ill Suh, Sang Gyu Kwak   +14 more
doaj   +1 more source

In vitro antiviral activity of the anti-HCV drugs daclatasvir and sofosbuvir against SARS-CoV-2, the aetiological agent of COVID-19 [PDF]

, 2021
Background: Current approaches of drug repurposing against COVID-19 have not proven overwhelmingly successful and the SARS-CoV-2 pandemic continues to cause major global mortality.
Castelo Branco, Frederico Silva, Chien, Minchen, Ferreira, Marcelo Alves, Rehen, Stevens K, Saraiva, Felipe B, Rajoli, Rajith KR, Amorim Fernandes, Tacio Vinicio, Boechat, Nubia, Fintelman-Rodrigues, Natalia, Dias Da Silva, Aline de Paula, Sacramento, Carolina Q, Garzia, Aitor, Temerozo, Jairo R, Tuschl, Thomas, Owen, Andrew, Ferreira, Andre C, Souza, Leticia RQ, de Freitas, Caroline S, Zaluar Guimaraes, Marilia, Bozza, Fernando A, Goto-Silva, Livia, Gomes Dias, Suelen da Silva, Vitoria, Gabriela, Soares, Vinicius Cardoso, Boas Hoelz, Lucas Villas, Pedrosa, Carolina SG, Bou-Habib, Dumith Chequer, Tao, Chuanjuan, Bozza, Patricia T, Souza, Thiago Moreno L, da Silva, Carine dos Santos, Jockusch, Steffen, Mattos, Mayara, Russo, James J, Xie, Wei, Wang, Xuanting, Pao, Camila RR, Bastos, Monica Macedo, Patel, Dinshaw, Ju, Jingyue, Andrew Owen, Aitor Garzia, Patel, Dinshaw J., André C Ferreira, Tácio Vinício Amorim Fernandes, Silva, Aline de Paula Dias da, Xuanting Wang, Rajith K R Rajoli, Saraiva, Felipe B., James J Russo, Marcelo Alves Ferreira, Dinshaw Patel, Silva, Livia Goto, Guimaraes, Marilia Zaluar, Caroline S de Freitas, Frederico Silva Castelo Branco, Russo, James J., Souza, Leticia Rocha Quintino, Wei Xie, Carine dos Santos da Silva, Steffen Jockusch, Aline de Paula Dias Da Silva, Rodrigues, Natalia Fintelman, Vinicius Cardoso Soares, Núbia Boechat, Jairo R Temerozo, Suelen da Silva Gomes Dias, Thiago Moreno L Souza, Natalia Fintelman-Rodrigues, Thomas Tuschl, Pão, Camila R. R., Tuschi, Thomas, Chuanjuan Tao, Dumith Chequer Bou-Habib, Bozza, Fernando A., Patrícia T Bozza, Silva, Carine dos Santos da, Camila R R Pão, Ferreira, André C., Rehen, Stevens K., Freitas, Caroline S. de, Gabriela Vitória, Rajoli, Rajith K. R., Felipe B Saraiva, Souza, Thiago Moreno L., Fernando A Bozza, Dias, Suelen da Silva Gomes, Letícia R Q Souza, Jingyue Ju, Carolina Q Sacramento, Hoelz, Lucas Villas Bôas, Marilia Zaluar Guimarães, Lucas Villas Bôas Hoelz, Stevens K Rehen, Mayara Mattos, Fernandes, Tácio Vinício Amorim, Livia Goto-Silva, Bozza, Patrícia Torres, Temerozo, Jairo Ramos, Pedrosa, Carolina S. G. P, Sacramento, Carolina Q., Mônica Macedo Bastos, Carolina S G Pedrosa, Minchen Chien, Castelo Brando, Frederico Silva   +104 more
core   +1 more source

The effectiveness of daclatasvir based therapy in European patients with chronic hepatitis C and advanced liver disease [PDF]

, 2017
Daclatasvir; Eficàcia; Hepatitis CDaclatasvir; Eficacia; Hepatitis CDaclatasvir; Effectiveness; Hepatitis CBackground There is limited evidence for the effectiveness of daclatasvir in patients whose hepatitis C threatens their life expectancy. The Named
Weis, Nina, Hofer, Harald, Young, Jim, Giostra, Emiliano, Irving, William, Weiland, Ola, Castells Fusté, Lluis   +6 more
core   +4 more sources

Modelling clinical data shows active tissue concentration of daclatasvir is 10-fold lower than its plasma concentration [PDF]

, 2014
OBJECTIVES: Daclatasvir is a highly potent inhibitor of hepatitis C virus. We estimated the active tissue concentration of daclatasvir in vivo. METHODS: We developed a mathematical model incorporating pharmacokinetic/pharmacodynamic and viral dynamics ...
Sun, Ren, Loverdo, Claude, Lloyd-smith, James O., Qi, Hangfei, Lloyd-Smith, James O, Wu, Nicholas C., Olson, C Anders, Wu, Nicholas C, Olson, C. Anders, Ke, Ruian   +9 more
core   +2 more sources

Sustained virological response to antiviral drugs in treatment of different genotypes of HCV cirrhotic patients

Pakistan Journal of Pharmaceutical Sciences, 2023
Cirrhosis and liver cancer are both caused by hepatitis C virus (HCV) infection of the liver. Patients with HCV cirrhosis may be treated with one of many antiviral medications, depending on their specific genotype.
Amin Ullah, Aqsa Maryam, Ghaffarul Malik, Hira Hameed, Kifayat Hussain, Junaid Ahmad, Ihteshamul Haq, Mohsina Haq, Reem M Aljowaie, Elsayed Mohsen Abougazia, Tse-Wei Chen, Jamshaid Ahmad, Kashif Bashir, Laiba Ahmad, Bashir Ahmad   +14 more
doaj   +1 more source